Autolus Therapeutics plc (FRA:6A3A)
Germany · Delayed Price · Currency is EUR 1.200
-0.050 (-4.00%)
At close: Nov 28, 2025
Autolus Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 51.13 | 10.12 | 1.7 | 6.36 | 2.33 | 1.72 | Upgrade |
| 51.13 | 10.12 | 1.7 | 6.36 | 2.33 | 1.72 | Upgrade | |
Revenue Growth (YoY) | 406.67% | 496.00% | -73.30% | 172.96% | 35.86% | -41.02% | Upgrade |
Cost of Revenue | 186.51 | 141.02 | 122.31 | 117.35 | 110.84 | 134.89 | Upgrade |
Gross Profit | -135.38 | -130.9 | -120.62 | -110.99 | -108.51 | -133.17 | Upgrade |
Selling, General & Admin | 138.56 | 109.89 | 54.91 | 31.9 | 31.87 | 34.97 | Upgrade |
Operating Expenses | 138.56 | 109.89 | 54.91 | 31.9 | 31.87 | 34.97 | Upgrade |
Operating Income | -273.94 | -240.79 | -175.53 | -142.89 | -140.37 | -168.15 | Upgrade |
Interest Expense | -11.39 | -9.29 | -45.07 | -8.91 | -1.11 | - | Upgrade |
Interest & Investment Income | 23.2 | 32.36 | 13.51 | 1.71 | 0.26 | 0.54 | Upgrade |
Currency Exchange Gain (Loss) | 13.15 | -0.99 | 2.64 | 1.8 | -2.3 | -0.2 | Upgrade |
Other Non Operating Income (Expenses) | 28.9 | 0.32 | 0.22 | 0.34 | 0.16 | 1.55 | Upgrade |
EBT Excluding Unusual Items | -220.08 | -218.4 | -204.23 | -147.95 | -143.36 | -166.26 | Upgrade |
Gain (Loss) on Sale of Assets | -0 | -0.22 | -3.79 | -0.52 | -0.68 | - | Upgrade |
Asset Writedown | - | -0.41 | -0.38 | - | - | - | Upgrade |
Other Unusual Items | -0.1 | -0.1 | - | -0.1 | 2 | - | Upgrade |
Pretax Income | -220.19 | -219.13 | -208.4 | -148.57 | -142.04 | -166.26 | Upgrade |
Income Tax Expense | 4.62 | 1.53 | -0.02 | 0.27 | 0.06 | -24.16 | Upgrade |
Net Income | -224.8 | -220.66 | -208.38 | -148.84 | -142.1 | -142.09 | Upgrade |
Net Income to Common | -224.8 | -220.66 | -208.38 | -148.84 | -142.1 | -142.09 | Upgrade |
Shares Outstanding (Basic) | 266 | 255 | 174 | 95 | 72 | 52 | Upgrade |
Shares Outstanding (Diluted) | 266 | 255 | 174 | 95 | 72 | 52 | Upgrade |
Shares Change (YoY) | 14.66% | 46.69% | 83.11% | 31.78% | 39.81% | 19.72% | Upgrade |
EPS (Basic) | -0.84 | -0.86 | -1.20 | -1.57 | -1.97 | -2.76 | Upgrade |
EPS (Diluted) | -0.84 | -0.86 | -1.20 | -1.57 | -1.97 | -2.76 | Upgrade |
Free Cash Flow | -285.22 | -228.35 | -156.57 | -123.15 | -126.72 | -132.44 | Upgrade |
Free Cash Flow Per Share | -1.07 | -0.90 | -0.90 | -1.30 | -1.76 | -2.57 | Upgrade |
Gross Margin | -264.79% | - | - | - | - | - | Upgrade |
Operating Margin | -535.79% | -2379.34% | -10337.34% | -2246.74% | -6024.64% | -9804.37% | Upgrade |
Profit Margin | -439.68% | -2180.45% | -12272.26% | -2340.24% | -6098.54% | -8285.36% | Upgrade |
Free Cash Flow Margin | -557.85% | -2256.38% | -9221.02% | -1936.31% | -5438.54% | -7722.39% | Upgrade |
EBITDA | -264.68 | -233.07 | -168.96 | -135.54 | -132.01 | -162.58 | Upgrade |
D&A For EBITDA | 9.26 | 7.72 | 6.57 | 7.36 | 8.37 | 5.57 | Upgrade |
EBIT | -273.94 | -240.79 | -175.53 | -142.89 | -140.37 | -168.15 | Upgrade |
Revenue as Reported | 51.13 | 10.12 | 1.7 | - | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.